Publications

 

Merrill J, et al. LSM 2018 – Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE.

View Publication

Ramsey-Goldman R, et al. LSM 2017 • Cell-bound complement activation products in SLE

View Publication

Buyon J, et al. LSM 2016 – Reduction in EC4d and anti-C1q antibodies associate with clinical improvement in SLE.

View Publication

Putterman C, et al. LSM. 2014. Cell_bound complement activation products in systemic lupus erythematosus.

View Publication

Wallace D, et al. LSM. 2016. Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products.

View Publication
 
Related to AVISE CTD / AVISE Lupus
AVISE Lupus is indicated for the diagnosis of suspected SLE patients. AVISE CTD is indicated for differential diagnosis of autoimmune connective tissue diseases.

Clinical Validity

Putterman C, et al. Lupus Science & Medicine. 2014. Cell bound complement activation products in systemic lupus erythematosus.

View Publication


Ramsey-Goldman R, et al. Arthritis & Rheumatology. 2019. Complement activation occurs in patients with probable systemic lupus erythematosus and may predict progression to ACR classified SLE.

View Publication


Wallace D, et al. Lupus Science & Medicine. 2016. Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products.

View Publication

Clinical Utility

Wallace D, et al. Lupus Science & Medicine. 2019. Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE. 

View Publication


Liang E, et al. Lupus Science & Medicine. 2020. Utility of the AVISE Connective Tissue Disease test in predicting lupus diagnosis and progression.

View Publication


Mossell J, et al. Open Rheumatology Journal. November 2016. The AVISE Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus.

View Publication

Health Economic Outcome Research

Clarke et al. Evaluation of the Economic Benefit of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using a Multivariate Assay Panel (MAP).

View Publication

Analytical Validity

Dervieux et al. Validation of multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus.

View Publication

SLE Review Articles

Mosca M, et al. Arthritis & Rheumatology. 2019. How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria.

View Publication


Meacock R, Dale N, Harrison MJ. The humanistic and economic burden of systemic lupus erythematosus: A systematic review. Pharmacoeconomics.

View Publication

Case Study

Lamichhane D, Weinstein A. Probable systemic lupus erythematosus with cell-bound complement activation products (CB-CAPS).

View Publication

Medical Society Guidelines

Aggarwal, Rohit et al. Distinctions between diagnostic and classification criteria?

View Publication

Publications related to CB-CAPs

Clinical Validity

Manzi et al. Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus.

View Publication


Kao AH, Navratil JS, Ruffing MJ, et al. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus.

View Publication


Liu CC, Kao AH, Hawkins DM, Manzi S, Sattar A, Wilson N, Ahearn JM. Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus.

View Publication


Yang et al. Usefulness of erythrocyte-bound C4d as a biomarker to predict disease activity in patients with systemic lupus erythematosus.

View Publication

Analytical Validity

Dervieux et al. Validation of multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus.

View Publication

CB-CAPs Review Articles

Ramsey-Goldman R, Li J, Dervieux T, et al Cell-bound complement activation products in SLE. Lupus Science & Medicine.

View Publication


Ahearn et al. Cell-bond complement activation products as lupus biomarkers: diagnosis, monitoring and stratification. Expert Review of Clinical Immunology.

View Publication

Publications related to PC4d

PC4d is indicated for diagnosed SLE patients as a marker associated with thrombosis.

Clinical Validity

Elisabet Svenungsson et al. Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus.

View Publication


Petri MA, Conklin J, O'Malley T, et al. Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE Lupus Science & Medicine.

View Publication


Kao AH, McBurney CA, Sattar A, Lertratanakul A, Wilson NL, Rutman S, Paul B, Navratil JS, Scioscia A, Ahearn JM, Manzi S. Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus.

View Publication

Publications related to AVISE MTX

Avise MTX is indicated for RA patients receiving Methotrexate therapy as an objective measure of therapeutic exposure.

Clinical Validity

Takahashi C, Kaneko Y, Okano Y, et al. Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study.

View Publication


Dervieux et al. Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis.

View Publication


Dervieux et al. Pharmacogentic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentered cross-sectional observation study.

View Publication


Dervieux et al. Pharmacogenomic and Metabolic Biomarkers in the Folate Pathway and Their Assoication With Methotrexate Effects During Dosage Escalation in Rheumatoid Arthritis.

View Publication

AVISE MTX Review Articles

Braun J. Methotrexate: Optimizing the Efficacy in Rheumatoid Arthritis. Therapeutic Advances in Musculoskeletal Disease.

View Publication


Kremer J. Toward a Better Understanding of Methotrexate. Arthritis and Rheum.

View Publication

Analytical Validity

Kelley Brady et al. Transition of Methotrexate Polyglutamate Drug Monitoring Assay from Venipuncture to Capillary Blood-Based Collection Method in Rheumatic Diseases.

View Publication

Publications related to AVISE HCQ

AVISE HCQ is indicated for SLE patients receiving Hydroxychloroquine therapy as an objective measure of therapeutic exposure.

Clinical Validity

Petri et al. Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy.

View Publication


Costedoat-Chalumeau et al. A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires.

View Publication


Costedoat Chalumeau N et al.

View Publication

AVISE HCQ Review Articles

Garg et al. The Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.

View Publication


Laura Durcan, William A. Clarke, Laurence S. Magder, Michelle Petri. The Journal of Rheumatology.

View Publication

Analytical Validation

Qu et al. Capillary blood collected on volumetric absorptive microsampling (VAMS) device for monitoring hydroxychloroquine in rheumatoid arthritis patients.

View Publication

Publications related to AVISE HCQ

Other Publications

Arriens C, Alexander RV, Narain S, et al. Cell-bound complement activation products associate with lupus severity in SLE. Lupus Science & Medicine.

View Publication


Hui-Yen et al. Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity.

View Publication

Abstracts

Petri M, Li J, Conklin J, O'Malley T, Ligayon J, Wolover L, Dervieux T. Role of Platelet C4d in Thrombosis and Lupus Nephritis [abstract].

View Publication


Gartshteyn Y, Mor A, Shimbo D, Khalili L, Kapoor T, Geraldino-Pardilla L, Alexander R, Dervieux T, Askanase A. Platelet-bound C4d Is Associated with Platelet Activation and Arterial Thrombotic Events [abstract].

View Publication


Gartshteyn Y, Alexander R, Conklin J, Dervieux T, Askanase A. Platelet-bound C4d Is Associated with an Increased Risk of Arterial and Venous Thromboses in SLE [abstract].

View Publication


Gartshteyn Y, Mor A, Geraldino L, Kapoor T, Chen T, Dervieux T, Askanase A. Platelet Bound Complement Split Product (PC4d) May Be a Marker of Platelet Activation and Cardiovascular Events in Systemic Lupus Erythematosus [abstract].

View Publication


Petri M, Li J, Brady K, Conklin J, O'Malley T, Dervieux T. Agreement of Hydroxychloroquine Blood Levels Between a University and Commercial Laboratory [abstract].

View Publication


Balbi V, Silva C, Pedrosa T, Pereira R, Campos L, Leon E, Duarte N, Carvalho V, Pasoto S, Rosario D, Brandao L, Bonfa E, Aikawa N. Hydroxychloroquine Blood Levels Predicts 6-Months Disease Activity in Juvenile Lupus Nephritis [abstract].

View Publication


Dervieux T, Kremer J, Brady K, Takahashi C, Takeuchi T, Kaneko Y. Enhanced Methotrexate Polyglutamation in Japanese as Compared to Caucasian Rheumatoid Arthritis Patients Starting Methotrexate [abstract].

View Publication


Garg S, Unnithan R, Hansen K, Costedoat-Chalumeau N, Bartels C. Meta-Analysis Examining the Clinical Significance of Monitoring of Hydroxychloroquine Levels in SLE [abstract].

View Publication


Petri M, Elkhalifa M, Goldman D, Magder LS, Singh M. Hydroxychloroquine Blood Levels Show Significant Trend Test for Risk of Retinopathy [abstract].

View Publication


Dervieux T, Kremer J, Brady K, Takahashi C, Takeuchi T, Kaneko Y. Enhanced Methotrexate Polyglutamation in Japanese as Compared to Caucasian Rheumatoid Arthritis Patients Starting Methotrexate [abstract].

View Publication


Dervieux T, Grosjean M, Jiang C, Brady K, Schmiegelow K, Kremer J, Yang J. Genetic Polymorphism in Dihydrofolate Reductase Impacts Methotrexate Polyglutamation in Adult Rheumatoid Arthritis [abstract].

View Publication


Dervieux T, Kremer JM, O'Malley T, Kivitz AJ, Conklin J, Weinblatt M. Differing Contribution of Methotrexate Polyglutamation to Infliximab and Adalimumab Exposure As Compared to Etanercept [abstract].

View Publication

Methotrexate polyglutamates (MTXPGs)

Brady K, et al. American Association for Clinical Chemistry. 2019. Transition of Methotrexate Polyglutamate Drug Monitoring Assay from Venipuncture to Capillary Blood-Based Collection Method in Rheumatic Diseases.

View Publication


Dervieux T, et al. Annals of the Rheumatic Diseases. 2018. Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept.

View Publication


Dervieux T, et al. Annals of the Rheumatic Diseases. 2012. Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis.

View Publication


Dervieux T, et al. Annals of the Rheumatic Diseases. 2005. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study.

View Publication


Dervieux T, et al. Arthritis & Rheumatism. 2006. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis.

View Publication


Kremer J. Arthritis & Rheumatism. 2004. Toward a better understanding of methotrexate.

View Publication


Dervieux T, et al. Clinical Chemistry. 2003. HPLC Determination of Erythrocyte Methotrexate Polyglutamates after Low-Dose Methotrexate Therapy in Patients with Rheumatoid Arthritis.

View Publications

Anti-Carbamylated Protein Antibodies (Anti-CarP)

Weinstein A, et al. The Journal of Rheumatology. 2019. Reevaluating Serologic Markers of Poor Prognostic Factors in Rheumatoid Arthritis.

View Publication


Shi J, et al. PNAS. 2011. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage.

View Publication

 

Abstracts

An Evaluation of the Economic Impact of Earlier Systemic Lupus Erythematosus  (SLE) Diagnosis Using Complement C4D Activation Products in a Multivariate Assay.

View Abstract


ACR Chicago 2018. Capillary Blood Based Methotrexate Polyglutamate Assay for Monitoring Low Dose Methotrexate Therapy in Rheumatic Diseases.

View Abstract


ACR Chicago 2018. Genetic Polymorphism in Dihydrofolate Reductase Impacts Methotrexate Polyglutamation in Adult Rheumatoid Arthritis.

View Abstract


ACR Chicago 2018 Complement C4d Split Products in Combination With lupus Anticoagulant and Low Complement Associate With Thrombosis in Systemic lupus erythematosus.

View Abstract


ACR San Diego 2017. Abnormalities in Complement System are Related to Disease Severity Index in Systemic lupus erythematosus.

View Abstract


ACR Chicago 2018 Diagnostic Performances of Antibodies Against Carbamylated Proteins in U.S. Rheumatoid Arthritis and Other Autoimmune Rheumatic Diseases.

View Abstract


ACR San Diego 2017. Complement Activation in Peripheral Blood in Relation to lupus, Antiphospholipid and Rheumatoid Arthritis Autoantibodies: Insights From Clinical Laboratory Evaluations.

View Abstract


ACR San Diego 2017. A Panel of lupus Biomarkers for the Monitoring of systemic lupus erythematosus: Performance Characteristics in Distinct SLE Cohorts.

View Abstract


ACR San Diego 2017. Abnormalities in Complement System are Related to Disease Severity Index in Systemic lupus erythematosus.

View Abstract


ACR San Diego 2017. Cell bound Complement Activation Products Distinguish systemic lupus erythematosus From Other Diseases Among Patients With High Antinuclear Antibody Titers and Normal Complement.

View Abstract


ACR San Diego 2017. Complement Activation in Peripheral Blood in Relation to lupus, Antiphospholipid and Rheumatoid Arthritis Autoantibodies: Insights From Clinical Laboratory Evaluations.

View Abstract


ACR Chicago 2018 Diagnostic Performances of Antibodies Against Carbamylated Proteins in U.S. Rheumatoid Arthritis and Other Autoimmune Rheumatic Diseases.

View Abstract


ACR San Diego 2017. Cell bound Complement Activation Products Distinguish systemic lupus erythematosus From Other Diseases Among Patients With High Antinuclear Antibody Titers and Normal Complement.

View Abstract